Astellas
Astellas Pharma is a Japan-based pharmaceutical company that develops, manufactures and supplies medicinal products for the healthcare industry.
Business Model:
Revenue: $10.2B
Employees: 10,001-999,999
Rankings
Industries / Tags:
Detailed Astellas Information
Geographic Data
Address: 2-5-1, Nihonbashi-Honcho
City: Tokyo
State: tōkyō prefecture
Zip: 103-8411
Country: JP
Financial Info
Stage:
grant
Raised Last:
$0
Raised Total:$0
Social
Metrics
237,871Website Global Rank
280,713Website Monthly Traffic
Twitter Followers
Description
Astellas Pharma is a Japan-based pharmaceutical company that develops, manufactures and supplies medicinal products for the healthcare industry.
Contact Phone:
Contact Email:
Astellas went public on 1/9/2009 on the Tokyo Stock Exchange
Listed Exchange:
Tokyo Stock Exchange
IPO Date:
1/9/2009
Ticker Symbol:
4503
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2012 | Telsar Pharma | Series A | 0 |
| 11/2021 | The National Comprehensive Cancer Network (NCCN) | Grant | - |
| 6/2008 | CoMentis | Series D | 0 |
| 10/2013 | Mitobridge | Series A | 0 |
| 12/2018 | Iota Biosciences | Series A | 0 |
| 10/2019 | LabCentral | Corporate Round | 13M |
| 11/2017 | Catalia Health | Grant | 0 |
| 2/2005 | FibroGen | Venture Round | 0 |
| 10/2022 | Taysha Gene Therapies | Post-IPO Equity | 50M |
| 11/2021 | The National Comprehensive Cancer Network (NCCN) | Grant | - |
| 10/2019 | LabCentral | Corporate Round | 0 |
| 12/2018 | Iota Biosciences | Series A | 0 |
| 11/2017 | Catalia Health | Grant | 0 |
| 10/2013 | Mitobridge | Series A | 0 |
| 4/2012 | Telsar Pharma | Series A | 0 |
| 6/2008 | CoMentis | Series D | 0 |
| 2/2005 | FibroGen | Venture Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 7/2020 | Grant | 1 | - |
National Institute on Drug Abuse (NIDA) National Institute on Drug Abuse (NIDA) National Institute on Drug Abuse (NIDA) National Institute on Drug Abuse (NIDA) |
7/2020 | Grant | - | 7/2020 | Grant | - |
National Institute on Drug Abuse National Institute on Drug Abuse |
7/2020 | Grant | 1 | - |
National Institute on Drug Abuse (NIDA) National Institute on Drug Abuse (NIDA) National Institute on Drug Abuse (NIDA) National Institute on Drug Abuse (NIDA) |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 10/2020 | Iota Biosciences | |
| 4/2020 | Nanna Therapeutics | |
| 12/2019 | Xyphos Biosciences | |
| 12/2019 | Audentes Therapeutics | |
| 12/2018 | Potenza Therapeutics | |
| 8/2018 | Quethera | |
| 2/2018 | Universal Cells Inc. | |
| 12/2017 | Mitobridge | |
| 4/2017 | Ogeda | |
| 10/2016 | Ganymed Pharmaceuticals |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
